W.L.Gore & Associates
Open enrollment with a later-stage pipeline tilt
According to ClinicalTrials.gov-derived indexes, W.L.Gore & Associates sits in the top decile of US sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count).
W.L.Gore & Associates: 53 sponsored US clinical trials, 11 recruiting.
W.L.Gore & Associates sponsors 53 registered US clinical trials on ClinicalTrials.gov, 11 of them currently recruiting, and 25 completed. 4 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Aortic Aneurysm, Thoracic, with 3 trials.
Top-decile sponsor footprint
W.L.Gore & Associates ranks in the top decile of sponsors by registered trial count (#359 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
25 of 32 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (78.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
53 total, page 2 of 2
GORE VIABAHN ENDOPROSTHESIS Peripheral Vascular Disease Study
NCT00228384
Evaluation of the GORE TAG Thoracic Endoprosthesis in the Treatment of Aneurysms
NCT00590759
GORE-TEX PROPATEN Vascular Graft Study
NCT00205790
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 2 |
| Phase 3 | 2 |
| Phase 4 | 2 |
Therapeutic Areas
Where W.L.Gore & Associates enrollment is open (later-stage tilt)
11 recruiting of 53 indexed (21% open); 25 completed (47%).
Phase mix: 4 late (III/IV) vs 2 early (I/II) (later-stage heavy).
Top condition: Aortic Aneurysm, Thoracic (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
W.L.Gore & Associates: open-pipeline peers nationwide
Peers matched on 53 registered trials and 21% open enrollment, not the therapeutic-area sidebar.
W.L.Gore & Associates sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 53 trials (± recruiting share)
- BioNTech SE · 53 trials · 36% recruiting
- Société des Produits Nestlé (SPN) · 53 trials · 2% recruiting
- Warner Chilcott · 53 trials · 0% recruiting
- AdventHealth Translational Research Institute · 54 trials · 24% recruiting
Sponsors near 21% open enrollment (± trial volume)
- Craig Hospital · 21% recruiting · 29 trials
- Georgia Institute of Technology · 21% recruiting · 24 trials
- University of Colorado, Denver · 21% recruiting · 1,283 trials
- Cedars-Sinai Medical Center · 21% recruiting · 339 trials
Related
What to do with this W.L.Gore & Associates page
53 registered trials is a research-attention snapshot, not an endorsement of W.L.Gore & Associates or any single study.
- 11 of W.L.Gore & Associates's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Aortic Aneurysm, Thoracic is the condition W.L.Gore & Associates studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Aortic Aneurysm, Thoracic trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
W.L.Gore & Associates pipeline card: 53 registered trials from official public datasets.Report a data error.